2017
article
Decreased darunavir concentrations during once-daily co-administration with maraviroc and raltegravir: OPTIPRIM-ANRS 147 trial
Claire Pressiat, Déborah Hirt, Jean‐Marc Tréluyer, Yi Zheng, Philippe Morlat, A. Naqvi, Laurent Tran, Jean‐Paul Viard, Véronique Avettand-Fènoël, C. Rouzioux, Laurence Meyer, Antoine Cheret, Bruno Hoën, C Bourdeaux, J. F. Delfraissy, C Goujard, Imane Amri, É. Le Fourn, Yann Quertainmont, M.Leonard Mole, A. Rami, A. Durel, Myriam Diemer, Maguy Parrinello, Thierry Allègre, Alain Lafeuillade, Gilles Hittinger, Véronique Lambry, M. Carrerre, G. Stevenson Philip, Claudine Duvivier, Paul‐Henri Consigny, C Charlier, Maryam Shoai, F. Touam, G Pialoux, Laurence Slama, Thomas L’Yavanc, Philippe Mathurin, A Adda, V Berrebi, D Salmon, E. Chakvetadze, T. Tassadit, E. Ousseima, M P Pietri, Yaniv Levy, A.-S. Lascaux, Jean‐Daniel Lelièvre, M Giovanna, Stéphanie Dominguez, C. Dumont, Christine Katlama, M A Valentin, Sophie Seang, L Schneider, N. Kiorza, Aziza Chermak, S Ben Abdallah, Anne Simon, F. Pichon, Michèle Pauchard, Jean‐Michel Molina, C Lascoux, Diane Ponscarme, N Colin De Verdière, Anne Scemla, Nathalie De Castro, A. Rachline, V Garrait, Willy Rozenbaum, Samuel Ferret, Suna Balkan, F Clavel, Mathieu Tourdjman, Matthieu Lafaurie, Ayşe Tana Aslan, Jérôme Goguel, S. Thierry, Victoire de Lastours, S. Gallien, J. Pavie, J. Delgado, C. Mededji, R. Verón, Sylvie Abel, S Pierre-François, C. Baringhton, J M Chennebault, Yves-Marie Vandamme, P Fialaire, S Rehaiem, V. Rabier, P. Abgueguen, M.A. Vandenhende, Nicole F. Bernard, D. Lacoste, Catherine Michaux, F Paccalin, M Receveur, S. Caldato, J. Delaune, J. M. Ragnaud, D. Neau, L. Lacaze-Buzy, J M Livrozet, François Jeanblanc, Djamila Makhloufi, F. Brunel Dalmas, Jean-Pierre Jourdain, Pierre Chiarello, P. Yéni, Bao Phung, C. Rioux, C. Godard, Françoise Louni, Neila Talbi, Glenn Catalano, F Guiroy, Jacques Reynes, Jeanne‐Marie Jacquet, V. Fauchere, Corinne Merle, V Lemoine, M Loriette, David Morquin, Alain Makinson, N. Atoui, C Tramoni, François Raffi, Clotilde Allavena, B. Bonnet, Sabelline Bouchez, Nicolas Feuillebois, C. Brunet‐François, Véronique Reliquet, O. Mounoury, P. Morineau-Le-Houssine, Éric Billaud, D. Brosseau, H Hüe, P. Dellamonica, Matteo Vassallo, A. Leplatois, J. Durant, Aurélien Joulié, Faouzi Souala, Claude Michelet, C Arvieux, P Tattevin, Henri‐Arthur Leroy, M Revest, F. Fily, J.-M. Chapplain, Céline Ratajczak, Guillaume Gras, Lise Bernard, J. F. Dailloux, V. Laplantine, L Cuzin, B. Marchou, S. Larrigue, Marie Chauveau, Florence Balsarin, M Obadia, Antoine Chéret, Stefan Bonné, T. Huleux, Faïza Ajana, I Alcaraz, V. Baclet, H. Melliez, N Viget, X. de la Tribonnière, E Aïssi, J Poissy, Isabelle Ravaux, Amanda Vallon, M. Varan, T May, L Letranchant, C. Burty, A. Briaud, S. Wassoumbou, Molly Stenzel, M P Bouillon, Y Debab, F. Caron, I. Gueït, C Chapuzet, Fanny Lebas, Manuel Etienne, P Miailhes, T. Perpoint, A. Sénéchal, I Schlienger, L. Cotte, C Normand, A. Boibieux, Tristan Ferry, Nadia Corsini, E Braun, J. Lippran, F Biron, Christian Chidiac, Sophie Pailhes, Jeffrey Lipman, J. Koffi, V. Thoirain, C. Brochier, A Greder Belan, A. Therby, Sylvie Monnier, M. Ruquet, Laurent Richier, Françoise Clary
1Citations signalées — pas une note de qualité
17Institutions déclarées
1Pays d’affiliation déclarés
Résumé fourni par la source
Background: The OPTIPRIM-ANRS 147 trial compared intensive combination ART (darunavir/ritonavir, tenofovir disoproxil fumarate/emtricitabine, raltegravir and maraviroc) started early during primary HIV-1 infection with standard tritherapy with darunavir/ritonavir, tenofovir disoproxil fumarate and emtricitabine. From month 6 to 18, the percentage of viral load values <50 copies/mL was lower in the pentatherapy arm than in the tritherapy arm. Here we compared antiretroviral drug concentrations between the two arms. Methods: Plasma samples were collected from 50 patients at various times after drug administration. A Bayesian approach based on published population pharmacokinetic models was used to estimate residual drug concentrations (Ctrough) and exposures (AUC) in each patient. A mixed linear regression model was then used to compare the AUC and Ctrough values of each drug used in both groups. Results: Published models adequately described our data and could be used to predict Ctrough and AUC. No significant difference in tenofovir disoproxil fumarate, emtricitabine and ritonavir parameters was found between the two arms. However, darunavir Ctrough and AUC were significantly lower in the pentatherapy arm than in the tritherapy arm (P = 0.03 and P = 0.04, respectively). Conclusions: Adding maraviroc and raltegravir to darunavir-based tritherapy decreased darunavir concentrations. Compliance issues, maraviroc-darunavir interaction and raltegravir-darunavir interaction were suspected and may affect the kinetics of viral decay during pentatherapy. A specific pharmacokinetic interaction study is needed to explore the interactions between darunavir and maraviroc and raltegravir.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Decreased darunavir concentrations during once-daily co-administration with maraviroc and raltegravir: OPTIPRIM-ANRS 147 trial
- Date Crossref
- 22/01/2018
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.
Institutions déclarées
Une affiliation ne permet pas de déduire la nationalité d’un auteur.
Sujets associés
HIV/AIDS drug development and treatmentHIV Research and TreatmentHIV/AIDS Research and Interventions